These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 16999648

  • 1. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.
    Jain R, Osei K, Kupfer S, Perez AT, Zhang J.
    Pharmacotherapy; 2006 Oct; 26(10):1388-95. PubMed ID: 16999648
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 3. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY.
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [Abstract] [Full Text] [Related]

  • 4. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

  • 5. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [Abstract] [Full Text] [Related]

  • 6. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, QUARTET Study Group.
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 8. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 9. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 10. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
    Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S.
    Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
    [Abstract] [Full Text] [Related]

  • 12. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A.
    Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484
    [Abstract] [Full Text] [Related]

  • 13. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P.
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [Abstract] [Full Text] [Related]

  • 14. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus.
    Rosenstock J, Corrao PJ, Goldberg RB, Kilo C.
    Clin Ther; 1993 Dec; 15(6):1031-40. PubMed ID: 8111800
    [Abstract] [Full Text] [Related]

  • 15. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M, Corsi A, Di Pietro C, Bellatreccia A, Mariz S, COM06 Study Investigators.
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [Abstract] [Full Text] [Related]

  • 16. Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study.
    Hsieh SH, Lin JD, Cheng HY, Ho C, Liou MJ.
    Clin Ther; 2006 Sep; 28(9):1318-26. PubMed ID: 17062305
    [Abstract] [Full Text] [Related]

  • 17. Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
    Esposito K, Maiorino MI, Di Palo C, Gicchino M, Petrizzo M, Bellastella G, Saccomanno F, Giugliano D.
    Diabetes Obes Metab; 2011 May; 13(5):439-45. PubMed ID: 21255215
    [Abstract] [Full Text] [Related]

  • 18. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
    Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q.
    J Clin Pharmacol; 2009 Oct; 49(10):1210-9. PubMed ID: 19622714
    [Abstract] [Full Text] [Related]

  • 19. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R, Kupfer S, Erdmann E, PROactive Study investigators.
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [Abstract] [Full Text] [Related]

  • 20. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
    Cooper MB, Al Majali K, Bailey CJ, Betteridge DJ.
    Clin Endocrinol (Oxf); 2008 May; 68(5):738-46. PubMed ID: 17980009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.